Events & Presentations

August 31, 2026, 14:00 CEST/ 8:00 am EDT/ 5:00 am PDT

Topic: Review SHASTA-3 and SHASTA-4 pivotal trial 12-month results

Q&A Participants: Gerald Watts, Borge Nordestgaard, and Arrowhead management

Title: Plozasiran in patients with severe hypertriglyceridemia: the SHASTA-3 and SHASTA-4 pivotal trial 12-month results

Session: HOT LINE 9 Late-breaking Science Session

Date/Time: August 30, 2026, 17:30 CEST

Presenter: Gerald Watts

Title: A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 (zodasiran) injection in Chinese adolescents and adults with homozygous familial hypercholesterolemia (HOFH)

Session: Late-breaking science: Beyond statins: the next wave of lipid-lowering therapies

Date/Time: August 31, 2026, 9:00 am CEST

Presenter: Zhuang Tian, Peking Union Medical College Hospital, Beijing, China

Title: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF PLOZASIRAN IN SUBJECTS WITH RENAL OR HEPATIC IMPAIRMENT
Session: Late Breaker Clinical Abstracts
Date/Time: May 26, 2026, 5:00 AM – 5:15 PM
Presenter: Jennifer Hellawell, MD

Title: A CASE REPORT OF A PREGNANT WOMAN WITH FAMILIAL CHYLOMICRONEMIA SYNDROME TREATED WITH PLOZASIRAN, A SMALL INTERFERING RNA AGAINST APOC3
Session: EAS stage: Outreach and case presentations
Date/Time: May 26, 2026, 8:30 AM – 10:30 AM
Presenter: Ann Mertens, MD

Title: Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM™ SC 
Date/Time: May 13, 2026, 4:45 PM EDT 
Presenter: Kayal Madhivanan

 

Title: Elevated Activin E levels correlate with insulin resistance and metabolic dysfunction in non-human primates and adult patients with obesity and type 2 diabetes 
Date/Time: May 13-14;  1:00 PM – 3:00 PM 
Presenter: Jane Kerr, MBChB, MPH, DRCOG